Kofnix SR tablet: Each sustained release tablet contains Butamirate Citrate INN 50 mg.
Kofnix syrup: Each 5 ml contains Butamirate Citrate INN 7.5 mg.
Kofnix ® is a preparation of Butamirate Citrate which is a non-opioid central cough suppressant. It acts on the cough center in the medulla oblongata. It is neither chemically nor pharmacologically related to opium alkaloids and is safer than codeine. In addition to its antitussive effect, it also exerts expectorant, moderate bronchodilatory action with anti-inflammatory effects. It decreases the airway resistance and improves blood oxygenation.
Kofnix ® SR 50 mg tablet: Adults: 2 to 3 tablets daily at 8 to 12 hours intervals for 5 to 7 days. Maximum duration is up to 2 months in chronic cases. Children (above 12 years): 1 to 2 tablets daily. Maximum duration is up to 2 months in chronic cases. Kofnix ® Syrup: Adults: 15 ml (3 teaspoonfuls) 4 times daily Children (above 12 years): 15 ml (3 teaspoonfuls) 3 times daily Children (6-12 years): 10 ml (2 teaspoonfuls) 3 times daily Children (3-below 6 years): 5 ml (1 teaspoonful) 3 times daily
Concomitant administration with expectorants or mucolytics causes mucus stasis and bronchospasm due to suppression of cough reflex (avoid combination).
It is contraindicated in patients with a known hypersensitivity to the active ingredient or any of the excipients.
Common: Skin rash, nausea, vomiting, diarrhea, dizziness, vertigo.
Overdose
Accidental overdose with Butamirate Citrate can cause the following symptoms: drowsiness, nausea, vomiting, diarrhea and hypotension. The usual emergency assistance should be taken: activated charcoal, saline laxative and symptomatic treatment should be given.
Category C (Contraindicated in 1st trimester). Avoid during first trimester; use in 2nd/3rd trimesters with caution only if indicated by physician. Lactation: Excretion in breast milk unknown; contraindicated during lactation.
Store below 25°C in a cool, dry place. Protect from light and moisture. Keep away from the reach of children.